Medindia

X

Valensa Granted Licenses for BiovaFlex(TM) Water-Soluble Egg Shell Membrane Ingredient

Friday, February 19, 2010 Drug News J E 4
Advertisement
Agreement Will Allow Valensa to Introduce State-of-the-Art Joint Health Formulations Featuring High Efficacy and Smaller Pill Sizes

For further information, contact:

Dr. Rudi Moerck, President & CEO

Voice: 352-357-2004 ext. 701

Fax: 352-483-2095

http://www.valensa.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Derma Sciences Featured on NJN News and WNET 13
S
Untreated Poor Vision in Elderly Linked to Dementi...